Repairon GmbH

Repairon GmbH, based in Göttingen, Germany, specializes in developing innovative regenerative therapies, primarily focusing on breakthrough technologies utilizing induced pluripotent stem cells (iPSCs) for heart disease treatment. Repairon GmbH was founded in 2014 in Göttingen, Germany. The company is dedicated to advancing regenerative medicine through the development of therapies specifically targeting heart failure. It has successfully completed one significant deal, with its most recent deal occurring on October 2, 2025.

The company does not have known subsidiaries or parent companies. Repairon GmbH specializes in the development and commercialization of innovative regenerative therapies, primarily focusing on induced pluripotent stem cell (iPSC) based technologies. The company's flagship product, Engineered Human Myocardium (EHM), consists of contractile heart tissue patches designed to address the critical medical need for treatments in patients experiencing advanced heart failure. These patches facilitate the remuscularization of the failing heart, aiming to restore function and enhance the quality of life for patients who currently have limited therapeutic options.

The target customer base includes healthcare providers and hospitals that serve advanced heart failure patients, with a focus on markets in Europe and North America, where the demand for such regenerative therapies is growing. Repairon GmbH's revenue model is primarily based on partnerships with healthcare institutions and potential direct sales to hospitals specializing in cardiac care. Transactions typically involve agreements where medical facilities acquire EHM patches for clinical use in heart failure patients, contributing to a revenue stream that supports the ongoing development of their technologies. The firm's pricing structure is designed to reflect the advanced technology and research invested in their flagship products, such as the EHM patches.

This pricing strategy may involve direct sales or collaborations with medical device distributors who facilitate access to their products in various geographical markets. In October 2025, Repairon GmbH raised an undisclosed amount of Series A funding led by new investor Bioventure Management GmbH, with participation from Sartorius AG. The company plans to use this funding to advance its heart therapy technologies and to initiate a European Phase 3 trial. Future growth plans also include expanding into new markets, particularly targeting regions in Europe and North America to meet the increasing demand for regenerative therapies.